PT - JOURNAL ARTICLE AU - Ahmadi, Armin AU - Huda, M. Nazmul AU - Bennett, Brian J. AU - Gamboa, Jorge AU - Zelnick, Leila R. AU - Smith, Lucas R. AU - Chondronikola, Maria AU - Raftery, Daniel AU - de Boer, Ian H. AU - Roshanravan, Baback TI - Chronic kidney disease is associated with attenuated plasma metabolome response to oral glucose tolerance testing AID - 10.1101/2022.01.08.22268946 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.08.22268946 4099 - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268946.short 4100 - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268946.full AB - Chronic kidney disease (CKD), a major public health problem, is associated with decreased anabolic response to insulin contributing to protein-energy wasting. Targeted metabolic profiling of the response to oral glucose tolerance testing (OGTT) may help identify metabolic pathways contributing to disruptions to insulin response in CKD. Using targeted metabolic profiling, we examined plasma metabolome in 41 moderate-to-severe non-diabetic CKD patients with estimated glomerular filtration rate (eGFR)<60ml/min per 1.73m2 (38.9±12.7) and 20 healthy controls with normal eGFR (87.2±17.7) before and after 2h of 75g oral glucose load. Compared to controls, CKD participants had higher lactate: pyruvate (L:P) ratio both at fasting and after oral glucose challenge. Total energy production estimated through GTP:GDP ratio was impaired during OGTT despite similar fasting GTP:GDP ratio. CKD group had sustained elevation of vitamin B family members, TCA cycle metabolites, and purine nucleotides in response to glucose challenge. Metabolic profiling in response to OGTT suggests a broad disruption of mitochondrial energy metabolism in CKD patients. These findings motivate further investigation into insulin sensitizers in patients with non-diabetic CKD and their impact on energy metabolism.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded in part by an unrestricted grant from the Northwest Kidney Centers and R01DK087726, R01DK087726-S1, R01DK129793-01 (BR), R01DK087726, R01DK087726-S1, K01 DK102851 (JAA, IHDB), K23DK100533 (JLG), K24 DK096574 (TRZ), and P30 DK017047 (University of Washington Diabetes Research Center) and Dialysis Clinics Incorporated, C-4122 (BR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review boards of University of Washington gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors